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Abstract
Background: Practices regarding hospitalisation of children at diagnosis of type 1 diabetes vary both within countries
and internationally, and high-quality evidence of best practice is scarce. The objective of this study was to close some
of the gaps in evidence by comparing two alternative regimens for children diagnosed with type 1 diabetes:
hospital-based care and hospital-based home care (HBHC), referring to specialist care in a home-based setting.
Methods: A randomised controlled trial, including 60 children aged 3–15 years, took place at a university hospital in
Sweden. When the children were medically stable, they were randomised to either the traditional, hospital-based care
or to HBHC.
Results: Two years after diagnosis there were no differences in HbA1c (p = 0.777), in episodes of severe
hypoglycaemia (p = 0.167), or in insulin U/kg/24 h (p = 0.269). Over 24 months, there were no statistically significant
differences between groups in how parents’ reported the impact of paediatric chronic health condition on family
(p = 0.138) or in parents’ self-reported health-related quality of life (p = 0.067). However, there was a statistically
significant difference regarding healthcare satisfaction, favouring HBHC (p = 0.002). In total, healthcare costs (direct
costs) were significantly lower in the HBHC group but no statistically significant difference between the two groups in
estimated lost production (indirect costs) for the family as a whole. Whereas mothers had a significantly lower value of
lost production, when their children were treated within the HBHC regime, fathers had a higher, but not a significantly
higher value. The results indicate that HBHC might be a cost-effective strategy in a healthcare sector perspective. When
using the wider societal perspective, no difference in cost effectiveness or cost utility was found.
Conclusions: Overall, there are only a few, well-designed and controlled studies that compare hospital care to
different models of home care. The results of this study provide empirical support for the safety and feasibility of HBHC
when a child is diagnosed with type 1 diabetes. Our results further indicate that the model of care may have an impact
on families’ daily living, not only during the initial period of care but for a longer period of time.
Trial registration: ClinicalTrials.gov with identity number NCT00804232, December 2008.
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Background
During the past decade, a rapidly increasing incidence of
type 1 diabetes has been reported from many parts of
the world with a shift towards a younger age of onset [1, 2].
In Sweden, the incidence rate has risen from 21.6 per
100.000 in 1978–1980 to 43.9 in 2005–2007; recent data
suggests a break in the increasing trend, but these findings
need to be confirmed over a longer period of time [3]. It is
a serious disease for the child, and it has significant implica-
tions also for the family as regards daily activities, work and
social life [4–6].
The disease also has substantial economic consequences
over time, both for individuals and society [7–11]. People,
diagnosed with diabetes during childhood, have been seen
to be disadvantaged in adult employment, with lower
earnings and lesser probability of attaining the highest
level of education, although late complications appear to
be the most important determinant of social consequences
in later life [8–11]. The findings emphasize the import-
ance of choosing an appropriate strategy for handling
diabetes already at the time of diagnosis.
The diagnosis of childhood diabetes represents a major
stressor event for parents [12–14] and parents approach
a challenging process of changes in the patterns of daily
activities [15]. Conventionally, a child newly diagnosed
with type 1 diabetes has been admitted to hospital as
part of his or her initial management, partly for child-
safety reasons, partly based on the belief that the family
needs time to adjust to the requirements of the disease
[16, 17]. Internationally, there is a considerable variation
in length of hospitalization at diagnosis but with a trend
towards shorter lengths of stay or exclusively outpatient
management [18–22]. In the United Kingdom, for
instance, children with newly diagnosed type 1 diabetes
are increasingly treated exclusively at home from diag-
nosis and onwards [5]. To obtain safe care in a home-
management environment requires adequate expert
support for parents, not least during the first days after
diagnosis, when parents still have limited knowledge
and understanding of the situation and its potential
risks [5]. Existing evidence is insufficient regarding the
consequences of alternative models of initial manage-
ment, both in perspectives of child, parents, health ser-
vices, and society [5, 12, 23]. Information on outcomes
in relation to resource use is necessary when strategic
decisions on the allocation of scarce healthcare re-
sources are made [24]; it is required by government
bodies in a large number of countries [25–27].
The objective of this study was to close some of the gaps
in evidence by comparing two alternative regimens for
children diagnosed with type 1 diabetes: hospital-based
care and hospital-based home care (HBHC), referring
to specialist care in a home-based setting. We have
previously reported on metabolic control, health-care
satisfaction and health-care costs one month after diagno-
sis [28]. In this paper, the focus is on metabolic control,
health-related quality of life, direct (i.e., healthcare) costs,
and indirect costs (i.e., productivity losses) two years after
diagnosis. Costs are related to metabolic control of the
child’s disease (cost-effectiveness analysis) and to health-
related quality of life of the parents (cost-utility analysis).
Methods
The study design was based on the British Medical Re-
search Council framework for development and evaluations
of Randomised Controlled Trials (RCT) for complex inter-
ventions [29, 30], and has been described in detail else-
where [31]. The study follows the Consolidated Standards
of Reporting Trials (CONSORT) recommendations [32].
Statistical power calculation included the primary outcome
HbA1c two years from diagnosis. In order to show a mean
difference of 10.5 mmol/mol (Mono S: one percent) be-
tween two groups with the power of 0.80 at a significance
level of 5%, it would take 30 children in each group. Ran-
domisation in two strata – (a) younger than eight years and
(b) eight years and above – was performed by an independ-
ent centre for clinical research, using the software R-2.6.1
[33]. The investigators received two sets of coded, sealed,
opaque envelopes, one for younger children and one for
older children.
Setting
The study took place from 1 March 2008 up to the end of
August 2011 at the Skåne University Hospital, division of
paediatrics at the Children’s Hospital in Lund, Sweden.
The study included children, aged 3–15 years and newly
diagnosed with type 1 diabetes. The age range of 3–15
was chosen to be as representative as possible of the forms
of care normally in practice. However, children younger
than three years were not included for the sake of their
safety. The follow-up of two years set the upper age limit
to 15 as the transition to the adult diabetes care setting
when the adolescents have had their 18th birthday. Add-
itional inclusion criteria were that the child did not have
any other difficult chronic illness, had no sibling with type
1 diabetes, was not in social-care custody, and lived in a
family who could understand and speak the Swedish
language. When the child was medically stable, he or she
received subsequent care according to the randomisation
procedure; either continued hospital-based care or HBHC.
After the first month, all families followed the conven-
tional care with visits at the outpatient department unit. A
flow chart through the phases of the trial up to the two-
year follow-up in September 2013 is shown in Fig. 1.
Hospital-based care
Children randomised to hospital-based care followed the
conventional care according to the Swedish national
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guidelines for paediatric diabetes [16], which involved
1–2 weeks [28] of hospital-based care, while child and
parent had educational sessions with the diabetes team
members. The information followed a check-list, where
each discipline was responsible for different portions of
information. One parent could stay at the hospital with
the child during the night and the other parent was
encouraged to be present during the educational ses-
sions. When the family had received most of the planned
information, they were able to be on a short leave from
the hospital before the child was actually discharged. For
children of school age, the diabetes nurse offered to
make a school-visit with the purpose of informing
teachers and school-friends about diabetes and insulin
treatment in addition to the outpatient visits offered by
the physician. Families in the hospital-based group had
access to telephone support from the diabetes nurse
during working-hours five days a week. During evenings,
nights and week-ends, they could receive assistance from
the general hospital staff.
Hospital-based home care
Children randomised to HBHC left the Children’s Hos-
pital together with their parents, when the child was
medically stable, and stayed at a Family House, placed in
the hospital area, up to a week [28]. The family house,
supported by a non-profit Child foundation, offers sick
children and their families a home-like environment
when the child is under care at the hospital. The stay
included support of a diabetes nurse during parts of the
day. Information meetings with other professionals in
the diabetes team were held at the Children’s Hospital in
accordance with the conventional care. The contents of
the information given to families were the same in both
groups. The active parts of the HBHC were defined as
an individualised learning process through supportive
interaction between the family and the diabetes nurse at
the Family House. Another active part included the
home-like environment which allowed families to prac-
tise the diabetes management with the concurrent
support. The final active part was an increased support
after discharge in the form of three home and/or school
visits by the diabetes nurse besides the regular diabetes
check visits as well as increased telephone access to the
diabetes nurse during day and evening, seven days a
week. During nights they could receive assistance from
the general hospital staff.
Health outcome measurements
Outcomes included extensive data from valid and reli-
able instruments and depending on type of outcomes,
data were collected at the time of discharge and at six,
12 and 24 months from diagnosis. Assessments included
metabolic control measured by glycated haemoglobin
(HbA1c), episodes of severe hypoglycaemia (defined as
unconsciousness with or without cramp), insulin regime
(multiple subcutaneous injections/insulin pump therapy)
and insulin U/kg/24 h. Assessments also included The
PedsQL™ Family Impact Module [34, 35] measuring
parents’ reported impact of paediatric chronic health
condition on the family, and The PedsQL™ Healthcare
Satisfaction Generic Module [36, 37], evaluating parents’
satisfaction with healthcare. Both PedsQL™ instruments
are scored on a 5-point (0–4) Likert-type scale for
the response categories. Parents reported health-
related quality of life was assessed by the Swedish SF-
36 [38–41]. The instrument includes 36 items measuring
parents reported physical and mental health and a single
item of parents reported health transition, compared to
one year ago. A research assistant, who was not involved
Fig. 1 Flow chart of the progress through the phases of the trial two years after diagnosis
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in care, collected the outcomes; and parents were
instructed to fill in the forms independently of each other.
HbA1c values and insulin units/kg/24 h were regis-
tered every third month. For cases without recorded
values at the designated time point of six, 12 and 24
months after diagnosis, values were weighted and inter-
polated between the two closest registrations. Episodes
of severe hypoglycaemia and the number of children
who changed insulin regime from multiple injections to
pump therapy were summed for the two years follow-
up. Insulin U/kg/24 h is presented from one time point
(24 months from diagnosis). The PedsQL™ scales were
linearly transformed into 0 to 100 scales as to facilitate
interpretation of the scores [36] and scale scores were
computed as the sum of the items divided by the
number of item answered [37]. For the PedsQL™ Family
Impact Module, higher scores indicate better functioning
and thus less negative impact on the family and for the
PedsQL™ Healthcare Satisfaction Generic Module, higher
scores indicate greater satisfaction.
For the SF-36, each question raw scores were coded,
recalibrated in two instances, summed, and transformed
into a scale from 0 (worst possible health state mea-
sured) to 100 (best possible health state) following the
standard SF-36 scoring algorithm [41]. Responses to the
SF-36 were used in order to produce utilities for the
cost-utility analysis, employing an accepted and validated
algorithm for SF-6D [42, 43]. Thus, the number of
dimensions was reduced from eight to six, including
totally 11 items; responses on items were weighted
according to the algorithm, producing scores between
minus one and plus one [42, 43]. Plus one is usually
interpreted as “perfect health”; zero as the equivalent
of “being dead”; negative values as states worse than
being dead.
Resource use measurements
Resource use measurements included both direct and
indirect costs. Direct costs comprised of hospital services
and health professional’s time use. Data on resource use
was obtained from the hospital patient-administrative
system and additional documentation. Cost per unit of
resource use was obtained from the administrative price-
list employed in between-hospitals transactions in 2011
[44]. Table 1 presents detailed information on type of
healthcare resource use and its unit cost. Indirect costs
included productivity losses as a result of parents’ and
relatives’ absence from work due to illness and treatment
of the child. Data on absence and earnings was collected
by questionnaires to parents or relatives of the child. Fol-
lowing the human capital approach, the number of days
that might have been used in labour-market work was
translated into monetary terms by multiplying with the
average daily wage rate including employer’s contribution
to social insurance and collectively agreed private insur-
ance premium. Individual data on incomes were used for
parents; however, due to lack of individual information, an
average wage rate was used for relatives and other carers.
Mean unit cost per day for fathers, mothers, and relatives
are shown in Table 1.
Statistical methods
Analyses were conducted using SPSSTM (version 22);
differences with p-values <0.05 were considered statisti-
cally significant. Descriptive statistics were used to report
Table 1 Unit cost of healthcare resource use and loss of
production in SEK 2011 level of prices
Healthcare resource use
Overnight (per night)
The Children’s hospital 5758
The Family house 556










Outpatient visit (per visit)
Paediatrician 1074
Other healthcare professionals 430
Home/School visit (per visit) 1290
Group education (per occasion) 430
Emergency visit (per visit) 2010
Loss of production per day
Parent/Relative (months from diagnosis) Mean (SD)
Fathers (0–1) 2852 (1373)
Fathers (1–6) 2887 (1222)
Fathers (6–12) 3602 (2950)
Fathers (12–24) 4169 (4178)
Mothers (0–1) 2038 (937)
Mothers (1–6) 2121 (859)
Mothers (6–12) 2189 (1017)
Mothers (12–24) 2328 (947)
aRelatives (0–24) 1569
Note: Unit costs were obtained from the Swedish southern regional healthcare
price list (year 2011)
Note: USD 1 = SEK 6.50, EUR 1 = SEK 9.03 (year 2011) average exchange
rate www.riksbank.se
aBased on mean income in Sweden for men and for women
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on parents’ background characteristics. Continuous vari-
ables were checked for distributional characteristics, and
since the data were assessed as normally distributed,
parametric tests were used [45]. Student’s t-test was
used to compare groups in HbA1c, episodes of severe
hypoglycaemia, number of children who changed insu-
lin regime from multiple injections to pump therapy
and insulin U/kg/24 h two years from diagnosis. Re-
peated measures ANOVA was used to analyse changes
in the child’s metabolic control with HbA1c (at six, 12
and 24 months from diagnosis), in the impact of paedi-
atric chronic health condition on family (at discharge,
six, 12 and 24 months from diagnosis), in parents’
healthcare satisfaction (at discharge, six, 12 and 24
months from diagnosis) and in health-related quality of
life with SF-6D (at discharge, 12 and 24 months from
diagnosis), and over time.
Results
The children’s medical variables and parent’s background
characteristics at diagnosis are presented in Table 2.
Health outcomes
Children’s mean HbA1c; measurements over time and
between group comparisons are presented in Table 3.
Two years after diagnosis, there were no differences in
HbA1c (mmol/mol) with a mean of 53.7 (SD 8.0) in the
hospital-based care and 53.1 (8.3) in the HBHC (p = 0.777),
in episodes of severe hypoglycaemia with a mean of
0.03 episodes in hospital-based care and 0.13 in HBHC
(p = 0.167), or in insulin U/kg/24 h with a mean of
0.85 (SD 0.30) in the hospital-based care and 0.94
(0.31) in the HBHC (p = 0.269). There were no differ-
ences in the number of children, who changed insulin
regime from multiple injections to pump therapy dur-
ing the two years’ follow-up with a mean of 0.23 (SD
0.43) in the hospital-based care and 0.27 in the HBHC
group (p = 0.770).
Of the total of 116 parents, 63 parents responded to
The PedsQL™ Family Impact Module (Table 4), and 58
parents responded to The PedsQL™ Healthcare Satisfac-
tion Generic Module (Table 5) at all the four time
points, and 76 parents responded to SF-36 at the three
time points, presented as SF-6D in Table 6. In the
measurements over time and between group compari-
sons, there were no statistically significant differences
between groups in how parents’ reported the impact
of paediatric chronic health condition on family (p = 0.138)
or in parents’ self-reported health-related quality of life
(p = 0.067). However, there was a statistically significant
difference regarding healthcare satisfaction, favouring
HBHC (p = 0.002).
Table 2 Children’s medical variables and parents background characteristics at diagnosis in hospital based care and HBHC
Hospital-based care HBHC
Children’s medical variables at diagnosis n = 30 n = 30
Boys/Girls, n 16/14 20/10
Age at diagnosis, mean (SD) 8.6 (3.8) 8.8 (3.7)
pH at diagnosis, mean (SD) 7.35 (0.08) 7.35 (0.11)
HbA1c (mmol/mol), mean (SD) 87.3 (28.7) 85.7 (26.4)
Parents background characteristics at diagnosis n = 58 n = 58
Mothers age, mean (SD) 40.4 (5.3) 40.1 (6.2)
Fathers age, mean (SD) 43.6 (6.6) 42.6 (5.7)
Education, n (%)
Mothers with university degree 18 (60.0) 15 (51.7)
Fathers with university degree 13 (46.4) 15 (50.0)
Working hours, n (%)
Mothers not employed 4 (13.3) 3 (10.3)
Mothers full time 19 (63.3) 12 (41.4)
Mothers part time, 7 (23.3) 14 (48.3)
Fathers not employed 1 (3.6) 0 (0.0)
Fathers full time 27 (96.4) 28 (96.5)
Fathers part time 0 (0.0) 1 (3.5)
Monthly income before tax, mean SEK (SD)
Mothers 26435 (13606) 22755 (8385)
Fathers 37295 (16550) 32629 (14832)
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Resource use
In total, over 24 months, healthcare costs (direct costs)
were significantly lower in the HBHC group, Swedish
Crown (SEK) 65 464 against SEK 81 676 for the hospital-
based care group (Table 7). This is mainly due to the fact
that initial care during the child’s first month was sig-
nificantly lower for HBHC. Home or school visits by a
diabetes nurse during the following 23 months were sig-
nificantly higher for the HBHC group, SEK 5 590 against
SEK 2451 for the hospital-based care group. Diabetes-
related re-admissions to hospital were also higher for the
HBHC group, but statistically insignificant.
In total, over 24 months, there was no statistically
significant difference between the two groups in esti-
mated lost production (indirect costs) for the family as a
whole (Table 8). Mothers had a significantly lower value
and fathers had a higher, but not a significantly higher
value, of lost production, in the HBHC regime than in
the hospital regime. When adding direct and indirect
costs together, no statistically significant difference was
observed (Table 8). The value of lost production de-
pends both on the number of days absent from work
and on the unit cost per day. No statistically significant
differences between the two treatment groups were
detected in the number of days absent from work,
neither for the groups in total (both genders), nor for
mothers and fathers analysed separately (Table 9).
Mothers had significantly more days absent from work
than fathers in the hospital group and in the study
population as a whole, but no significant difference was
detected between fathers and mothers in the HBHC
group/Table 9). Fathers had a significantly higher unit
cost than mothers both in the HBHC group and in the
hospital group (Table 9).
Cost effectiveness and cost utility
The cost-effectiveness and cost-utility analyses relate
costs to effectiveness in terms of HbA1C and to utility
in terms of SF-6D.
Since no statistically significant differences between
the intervention group and the control group regarding
HbA1c or SF-6D were found, and since statistically
significantly lower healthcare costs were found, the
results indicate that HBHC might be a cost-effective
strategy in a healthcare sector perspective. However,
when adding the indirect costs of lost production to the
direct healthcare costs, no statistically significant differ-
ence was found. Thus, when using the wider societal
perspective, no difference in cost effectiveness or cost
utility was found.
Discussion
This study compared two different regimens for the
initial management of children diagnosed with type 1
diabetes; hospital-based care and hospital-based home
are (HBHC). The results two years from diagnosis could
not detect any statistically significant difference between
the two groups as concerns efficacy and child safety in
terms of metabolic control and episodes of severe
hypoglycaemia. This is in line with the earlier follow-up
from the same study [28, 46, 47] and with another recent
Table 3 Children’s mean HbA1c; measurements over time and
between group comparisons
Repeated measures ANOVA Mean SD Significance 95 % Cl
HbA1c between group comparison p = 0.907
Control group (n = 30) 48.5 46.2–51.0
6 month 43.3 5.9 41.0–45.7
12 months 48.6 7.2 45.5–51.7
24 months 53.7 8.1 50.7–56.7
Intervention group (n = 30) 48.4 46.0–50.8
6 month 42.8 7.1 40.4–45.2
12 months 49.2 9.7 46.0–52.3
24 months 53.1 8.3 50.1–56.1
Table 4 Impact of paediatric chronic health condition on family; measurements over time and between group comparisons
Repeated measures ANOVA Mean SD Significance 95 % Cl
Family impact between group comparison p = 0.138
Control group (n = 29) 71.1 12.5 66.3–75.8
At discharge 65.3 14.3 59.9–70.7
6 month 76.1 13.7 70.9–81.4
12 months 72.5 13.9 67.2–77.8
24 months 76.1 13.7 70.9–81.4
Intervention group (n = 34) 75.8 12.3 71.5–80.0
At discharge 67.7 14.1 62.8–72.6
6 month 77.6 14.5 72.5–82.7
12 months 77.4 13.3 62.8–72.6
24 months 80.6 15.7 74.8–85.7
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retrospective study comparing different sites for initial
diabetes education [17].
Even though no statistically significant difference could
be detected in the present study, there might still be real
but not detected differences in the population at large.
When interpreting results, one must hence also take into
consideration the difference that the study was powered
to detect [48]. Even though our power calculations were
performed prior to the study and at the time, with an
estimated clinically relevant difference of HbA1c, the
defined effect in HbA1c might not be a likely effect size
as to expect. However, there is a balance to be made
between sample size and external validity over variation
in settings by the period of recruitment. Treatment
manuals were used and checked regularly but healthcare
evolves continuously. This was evident in the routines of
a gradually increased number of outpatient visits to the
diabetes nurse in the hospital-based care [28, 47]. Health-
care is inherently complex and a potential problem occurs,
when results of studies that have been performed under
circumstances that are not representative of the forms
of care normally in practice, are generalized to uncon-
trolled circumstances [49, 50]. Since the intervention
was intended to be implemented within clinical prac-
tice, if found to be a safe and effective way of caring for
a child, there needed to be a balance between the valid-
ity of inference and the implementation of care [48].
The response rate at 24 months was lower than at
previous follow-ups, probably explained by changed rou-
tines of data-collection. In the first years, a research
assistant who was not involved in the care assessed the
outcomes and booked appointments with families out-
side the hospital in order to let them answer the ques-
tionnaires. Since the inclusion of families took longer
than planned, we needed to change the routines, imply-
ing that the questionnaires were sent home by mail with
a return envelope to the families instead. This might
have brought in variability in the final outcomes. How-
ever, the results from the 24 month follow-up are in line
with the earlier follow-up of the same study. Even
though no statistically significant difference could be
detected in parents’ reporting on the impact of a chronic
paediatric health condition and parents’ health-related
quality of life, the direction of effect might indicate that
the initial management and the initial support given to
families have an impact on families’ future experiences
Table 5 Parents’ healthcare satisfaction; measurements over time and between group comparisons
Repeated measures ANOVA Mean SD Significance 95 % Cl
Healthcare satisfaction; between group comparison p = 0.002*
Control group (n = 29) 76.2 17.0 69.7–82.7
At discharge 73.1 21.6 64.9–81.3
6 month 77.9 20.9 70.0–85.9
12 months 78.7 17.0 72.3–85.2
24 months 74.9 22.8 66.2–83.6
Intervention group (n = 29) 88.4 10.5 84.4–92.5
At discharge 90.7 7.9 87.7–93.7
6 month 90.7 12.1 86.1–95.4
12 months 85.7 15.7 79.7–91.7
24 months 86.7 14.2 81.3–92.0
*p < 0.05
Table 6 Parents’ self-reported health-related quality of life (SF-6D), measurements over time and between group comparisons
Repeated measures ANOVA Mean SD Significance 95 % Cl
SF-6D between groups comparison p = 0.067
Control group (n = 40) 0.775 0.749–0.802
At discharge 0.746 0.109 0.710–0.782
12 months 0.774 0.107 0.742–0.807
24 months 0.805 0.102 0.773–0.837
Intervention group (n = 36) 0.811 0.783–0.839
At discharge 0.783 0.121 0.745–0.821
12 months 0.832 0.098 0.798–0.866
24 months 0.818 0.100 0.784–0.851
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Table 7 Healthcare costs (direct costs) in hospital-based care and HBHC, respectively, from diagnosis to 24 months after diagnosis
Hospital-based care (n = 30) HBHC (n = 30) p-value*
SEK SEK
Mean (SD) Mean (SD)
The initial care (0–1 month) 64279 (16928) 45022 (7909) <0.001*
Outpatient visit (1–24 months)
Paediatrician 9845 (1264) 9379 (1737) 0.240
Diabetes nurse 1820 (1418) 487 (675) <0.001*
Other professionals (Social worker, Dietician, Psychologist) 1404 (1059) 1161 (620) 0.282
Home/School visit by Diabetes nurse (1–24 months) 2451 (1866) 5590 (5580) 0.005*
Group education by Diabetes nurse and/or Dietician 559 (630) 373 (514) 0.215
Visits in relation to insulin pump introduction 330 (684) 430 (806) 0.605
Diabetes related emergency visits 603 (1075) 335 (927) 0.305
Diabetes related re-admissions 384 (2103) 2687 (12 717) 0.332
Total costs (1–24 months) 17 397 (4210) 20 443 (14 594) 0.277
Total costs (0–24 months) 81 676 (18 779) 65 464 (16 298) 0.001*
Note: USD 1 = SEK 6.50, EUR 1 = SEK 9.03 (year 2011) average exchange rate www.riksbank.se
*p < 0.05
Table 8 Loss of production (indirect costs) due to parents’ and relatives’ absence from work related to the child’s diabetes diagnosis
and a summary of direct and indirect costs related to the child’s diagnosis
Relation (months from diagnosis) n Hospital-based care n HBHC CI of the difference p-value
SEK Mean (SD) SEK Mean (SD) Lower - Upper
Fathers (0–1) 22 30 606 (45 387) 26 34 490 (36 148) −27 574 19 806 0.743
Fathers (1–6) 21 12 819 (20 110) 22 34 045 (59 059) −48 635 6 182 0.123
Fathers (6–12) 23 19 707 (70 008) 20 17 154 (25 000) −30 810 35 916 0.878
Fathers (12–24) 14 7 956 (10 685) 16 4 527 (9 234) −4 017 10 877 0.354
Fathers (sum of 0–24) 19 078 (46 102) 24 834 (39 896) −19 115 7 602 0.396
Mothers (0–1) 26 35 362 (22 138) 28 26 526 (21 121) −2 978 20 649 0.139
Mothers (1–6) 24 26 482 (52 562) 26 19 050 (31 356) −16 955 31 819 0.543
Mothers (6–12) 24 22 321 (38 353) 20 5 849 (14 026) −1 802 34 746 0.076
Mothers (12–24) 16 15 844 (18 559) 16 4 625 (6 926) 857 21 580 0.035*
Mothers (sum of 0–24) 26 046 (36 574) 15 878 (23 358) 1 141 19 196 0.027*
Parents (0–1) 48 33 182 (34 451) 54 30 361 (29 321) −9 708 15 351 0.656
Parents (1–6) 44 20 563 (41 290) 47 26 474 (46 584) −24 295 12 472 0.524
Parents (6–12) 47 21 042 (55 509) 40 11 501 (20 811) −8 937 28 017 0.308
Parents (12–24) 30 12 163 (15 664) 32 4 576 (8 029) −1 147 14 028 0.022*
Parents (sum of 0–24) 169 22 789 (41 323) 173 20 175 (35 577) −5 290 10 519 0.516
Relatives (0–24) 5 12 560 (14 346) 13 7 125 (5 031) −12 182 23 052 0.451
aSum families (0–24) 23 161 (41 316) 20 710 (32 898) −5 484 10 385 0.544
Sum direct and indirect costs (0–24) 30 220 270 (166 253) 30 176 769 (95 213) −26 516 113 519 0.219
Note: USD 1 = SEK 6.50, EUR 1 = SEK 9.03 (year 2011) average exchange rate www.riksbank.se
*p < 0.05
a Parents and relatives together
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of living with a child diagnosed with diabetes. Although
fathers had significantly higher incomes than mothers
and, hence, higher lost value of production per day
absent from work in both the HBHC group and the
hospital group, there was a significant difference
between the two genders in the number of days absent
from work only for the hospital group (in which mothers
had twice the number of days of absence than fathers).
In a qualitative evaluation of this RCT study [51], the
and learning conditions in HBHC seemed to support
partnership and collaboration. The parents in HBHC
described how they became active participants in
Table 9 Extended analysis of loss of production including parents’ number of days absent from work and the unit cost per day,
during the period 0–24 months from diagnosis
Students’ T-test na Mean SD Significance
Parents’ number of days absent from work
Comparisons between groups
Both genders
Control group 169 8.01 11.92
Intervention group 173 8.01 11.33 0.996
Mothers
Control group 90 10.71 13.84
Intervention group 90 8.26 11.42 0.196
Fathers
Control group 79 4.92 8.33
Intervention group 83 7.75 11.29 0.071
Comparisons between genders
Both groups
Mothers 180 9.48 12.71
Fathers 162 6.37 10.03 0.012
Control group
Mothers 90 10.71 13.84
Fathers 79 4.92 8.33 0.001
Intervention group
Mothers 90 8.26 11.42
Fathers 83 7.75 11.29 0.796
Unit costs per day (SEK)
Comparison between groups
Both genders
Control group 169 2855 1615
Intervention group 173 2542 2271 0.143
Comparisons between genders
Both groups
Mothers 180 2150 936
Fathers 162 3304 2570 0.000
Control group
Mothers 90 2409 1119
Fathers 79 3363 1924 0.000
Intervention group
Mothers 90 1891 612
Fathers 83 3248 3072 0.000
Note: USD 1 = SEK 6.50, EUR 1 = SEK 9.03 (year 2011) average exchange rate www.riksbank.se
aThe parents included in the analysis represent the parents of totally 60 children, who were asked for information of absent from work and income for each of
the four follow-up periods
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negotiations of daily management and decision making
in contrast to their passive role in the hospital-based
care. Although the difference among parents in the two
groups may be due to some underlying factor not
controlled for, an interpretation might also be that the
main active component in the HBHC has supported
the fostering of parents’ responsibility.
Parents in HBHC have, in the earlier follow-up con-
sistently reported significantly greater satisfaction with
healthcare compared to parents in the hospital-based
care [28, 46, 47]. Despite that difference in the manage-
ment between groups only involved the first month from
diagnosis, parents continued to report a significantly
greater level of satisfaction with the healthcare two years
from diagnosis. In addition to the home-like environ-
ment, the individualised learning process was an im-
portant part of the intervention bringing a focus on
normalization, supporting the family to find strategies as
to achieve good glycaemic control in combination with a
re-establishment of their normal lifestyle. In the qualita-
tive evaluation of the study the hospital-based care was
considered as being safe but not family- or diabetes-
oriented [51]. The HBHC was described as a relaxed
environment, providing individualized accessibility and
possibilities for situational learning and was considered
as more flexible, promoting normality and involvement.
This is in line with what others have found when chil-
dren and young people described inflexibility in clinic
processes and the dissonance this represented as com-
pared to families’ expectations of a normal life [6].
Parents who experienced hospital-based care when their
child was diagnosed with diabetes felt as if their role
as parents, the person the child could rely on, was
taken away from them [14]. This made them and
their families feel insecure; so holding on to the hos-
pital routines that they initially learned [12] might be
one way of feeling more in control in a distressing
and life-changing event.
As for our economic analyses, it should be observed
that the project included no collection of data on other
direct and indirect costs besides healthcare and lost
market production value, even though there might have
been substantial changes in families’ use of time and
other resources; see discussion above. Another drawback
is the fact that sample size was not chosen with the aim
to detect significant differences in costs and utility.
Thus, there might be real but not detected differences in
cost effectiveness and cost utility due to study design.
However, since the difference in SF-6D between the two
groups had as low p-value as 0.067, and since the health-
care satisfaction index showed a statistically significant
higher value, it should be fairly safe to conclude that
HBHC is a cost-effective strategy, at least in a narrow
healthcare sector perspective.
In line with available estimates of the cost of diabetes
disease to society at large [7, 8], we found that the indir-
ect costs of lost production were substantially higher
than the direct healthcare costs in both care groups.
This fact is worth noticing, even though no significant
difference could be observed between the two groups.
The dominance of indirect costs also meant that no
significant difference could be detected in total costs
(direct and indirect costs together). So, whether HBHC
might be cost-effective also in a wider societal perspec-
tive remains to be shown. Both perspectives are import-
ant for policy-makers. In some countries, the United
Kingdom, for instance, government authorities recom-
mend the healthcare perspective to be used, when
allocating resources in the National Health Service [27],
whereas in other counties, for instance, Swedish central
government authorities use the societal perspective [26].
Conclusions
Few studies have provided high-quality evidence when
comparing hospital-based care with different models of
home-based care. The results of this study support the
safety and feasibility of HBHC, when a child is diagnosed
with Type 1 diabetes. Our results further suggest that
the initial period of care and the strategies for diabetes
management that are first presented to the family may
exert an impact on families’ daily living for a longer
period of time. The results also suggest that HBHC is a
cost-effective strategy, at least in a narrow healthcare
sector perspective.
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